Can you stack BPC-157 with GHK-Cu?

BPC-157 and GHK-Cu are compatible in practice. Common protocols pair BPC-157 subcutaneous for systemic healing with topical GHK-Cu for skin, hair, and collagen support, or subcutaneous GHK-Cu for more systemic connective tissue benefits. They act through different mechanisms and do not compete.

BPC-157 + GHK-Cu Stack: Dosing, Mechanisms, and Use Cases

Why Stack These Two Peptides

BPC-157 and GHK-Cu (glycyl-histidyl-lysine copper peptide) work on different but complementary aspects of tissue repair and anti-aging:

BPC-157: angiogenesis, fibroblast migration, gut and soft-tissue repair, anti-inflammatory signaling
GHK-Cu: collagen and elastin synthesis, skin regeneration, hair follicle signaling, copper-dependent enzyme function, anti-inflammatory and antioxidant effects

There's no significant mechanistic overlap, which is why they combine cleanly without duplicating effort.

Most Common Use Cases for the Stack

Skin and hair optimization — topical GHK-Cu for cosmetic/skin/hair benefit, subcutaneous BPC-157 for systemic recovery
Comprehensive anti-aging protocols — paired with NAD+ or growth hormone secretagogues
Post-surgical aesthetic recovery — facial surgery, scar optimization
Extensive soft-tissue injuries — combining BPC-157's rapid-repair signaling with GHK-Cu's collagen-remodeling effects

Typical Protocols

Topical GHK-Cu + Subcutaneous BPC-157

GHK-Cu serum 0.05–2% applied to skin or scalp 1–2× daily
BPC-157 250–500 mcg subcutaneously daily
Cycle length 8–12 weeks

Subcutaneous GHK-Cu + Subcutaneous BPC-157

GHK-Cu 1–2 mg subcutaneously 2–3× per week
BPC-157 250–500 mcg subcutaneously daily
Inject at different sites, different syringes
Cycle length 6–8 weeks

Do Not Mix in the Same Syringe

Same principle as the Wolverine Stack — separate syringes, separate sites. Mixing peptides with different reconstitution conditions invites chemical interaction and sterility compromise. Back-to-back injections at the same visit are fine; a single mixed syringe is not.

Safety Considerations

Both peptides have a generally favorable short-term safety profile
Injection-site reactions are the most common side effect with either
GHK-Cu contains copper — people with Wilson's disease or copper overload conditions should avoid it
Angiogenesis is a shared mechanism with BPC-157 — same cancer caution applies
Topical GHK-Cu has minimal systemic absorption; subcutaneous GHK-Cu reaches systemic circulation

When the Stack Is Overkill

For simple uses — a single tendon injury, isolated gut issue — BPC-157 alone is usually enough. Adding GHK-Cu increases cost and complexity without clear incremental benefit if the problem doesn't have a collagen-remodeling or skin component. Reserve the stack for use cases that actually need both.

See BPC-157 and GHK-Cu guides. Related: Wolverine Stack dosage.